Microorganisms transform inexpensive carbon sources into highly functionalized compounds without toxic by-product generation or significant energy consumption. By redesigning the natural biosynthetic pathways in an industrially suited host, microbial cell factories can produce complex compounds for a variety of industries. Isoprenoids include many medically important compounds such as antioxidants and anticancer and antimarial drugs, all of which have been produced microbially. While a biosynthetic pathway could be simply transferred to the production host, the titers would become economically feasible when it is rationally designed, built, and optimized through synthetic biology tools. These tools have been implemented by a number of research groups, with new tools pledging further improvements in yields and expansion to new medically relevant compounds. This review focuses on the microbial production of isoprenoids for the health industry and the advancements though synthetic biology.

**INTRODUCTION**

Microbial biosynthesis of natural products provides advantages over biomass extraction and chemical synthesis. The native hosts of the natural products, usually plants, grow slowly with differences in the plant's climate and geography, leading to detrimental variations in the product concentration and composition (Chang and Keasling, 2006; Asadollahi et al., 2008; Engels et al., 2008). In addition, biomass extraction often requires substantial energy and resource consumption for miniscule product recovery (Martin et al., 2003; Shiba et al., 2007; Ajikumar et al., 2008). Chemical synthesis struggles to create the natural product's integral complexity (Chang and Keasling, 2006; Engels et al., 2008; Nakagawa et al., 2011). It also requires significant amounts of energy while producing toxic by-products (Chemler et al., 2006; Winter and Tang, 2012; Wu et al., 2013). Microbial biosynthesis of natural products can help avert these problems. The biosynthetic pathway from the native host is redesigned in a tractable platform organism, often *Escherichia coli* or *Saccharomyces cerevisiae*, which serves as a microbial cell factory (Shiba et al., 2007; Ajikumar et al., 2008; Albertsen et al., 2011; Du et al., 2011; Misawa, 2011). The microbes can utilize inexpensive carbon sources with short doubling times to produce highly functionalized and value-added products with no toxic by-products (Chemler et al., 2006; Ajikumar et al., 2008; Tang and Zhao, 2009; Hong and Nielsen, 2012). Microbial biosynthesis is well suited for the production of many natural products, including isoprenoids.

Isoprenoids are important secondary metabolites for the health industry. Built from five carbon isoprene units that are cyclized, rearranged, and adorned in a multitude of ways, isoprenoids, sometimes called terpenoids, include more than 40,000 structurally unique compounds (Chang and Keasling, 2006; Ajikumar et al., 2008; Farhi et al., 2011). Terpenoids are classified based on their number of isoprene units. Monoterpenes consist of two isoprene units, with sesquiterpenes, diterpenes, triterpenes, and carotenoids (or tetraterpenes) built from three, four, six, and eight isoprene units, respectively (Withers and Keasling, 2007; Asadollahi et al., 2008; Misawa, 2011; Walter and Strack, 2011). Important compounds for the health industry can be found in many of the terpenoids classes, including the carotenoid lycopene, the sesquiterpene artesminin, the diterpene paclitaxel, and triterpene herbal medicines (Das et al., 2007; Ajikumar et al., 2008; Asadollahi et al., 2008; Misawa, 2011).

Synthetic biology tools can help boost the delivery of isoprenoids to market. While the natural biosynthetic pathway could be simply transferred to an industrially suited host, such as *E. coli* or *S. cerevisiae*, the final titers of the desired product would become economically feasible when the pathway is rationally designed, built, and optimized (Klein-Marcuscharmer et al., 2007; Maury et al., 2008; Anthony et al., 2009). While reasonable titers for the commercial-scale production are currently unknown, a review indicates that 0.5 g/l is an adequate starting point for high value compounds (Ajikumar et al., 2008). Innovations in genomics and systems biology have facilitated the ability to engineer biology for commercial applications through a set of clear steps (Ajikumar et al., 2008; Keasling, 2012). First, the metabolic pathways needed to produce the desired products are selected. Second, a host suitable for industrial production and genetic manipulation is chosen. Third, what must be redesigned for the pathway and host to operate together is determined, followed by optimization so that production can become commercially relevant (Jarboe et al., 2010). These steps have been implemented by a number of research groups for the creation of biofuels, commodity chemicals, and products for the health industry. This review focuses on the microbial production of isoprenoids for the health industry and the advancements through synthetic biology. Four of the 10 isoprenoids discussed (Table 1)
| Isoprenoid         | Approach                                                | Microbial production (fold improvement)                                                                 | Microbe | Natural source and extraction                                      | Chemical synthesis                                      |
|-------------------|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------|---------|-------------------------------------------------------------------|----------------------------------------------------------|
| Amorphadiene²     | Express heterologous pathway in two operons and codon-optimize amorphadiene synthase           | 24 mg caryophyllene equivalent/l (300-fold) (Martin et al., 2003)                                        | E. coli | Artemisia annua 0.01–1.0% of dry leaf weight (Liu et al., 2006)   | 29–42% Overall yield (Zhu and Cook, 2012)               |
|                   | Redesign the mevalonate pathway to increase FPP and express Artemisia annua’s amorphadiene synthase and cytochrome P450 | 153 mg/l (500-fold) (Ro et al., 2006)                                                                    | S. cerevisiae |                                                                  |                                                          |
|                   | Identify the limiting reaction enzymes and balance gene expression through plasmid copy number and promoter strength | 293 mg/l (7-fold) (Anthony et al., 2009)                                                                   | E. coli |                                                                  |                                                          |
|                   | Overexpress every enzyme in the mevalonate pathway as well as modify fermentation conditions | 40 g/l (250-fold) (Westfall et al., 2012)                                                                  | S. cerevisiae |                                                                  |                                                          |
|                   | Express heterologous pathway in a strain of Streptomyces avermitilis with minimized genome | 30 mg/l (from 0 mg/l) (Komatsu et al., 2010)                                                              | S. avermitilis |                                                                  |                                                          |
|                   | Truncate and deregulate HMG1 and co-localize heterologous FDP synthase and amorphadiene synthase to the mitochondria | 20 mg/l (20-fold) (Farhi et al., 2011)                                                                   | S. cerevisiae |                                                                  |                                                          |
| Astaxanthin       | Overexpress native idi and gps from Archaeoglobus fulgidus and express the gene cluster crtB1Y2V from Agrobacterium aurantiacum | 1.4 mg/g dww (50-fold) (Wang et al., 1999)                                                                | E. coli | Haematococcus microalgae 1.5–3.0% by dry weight (Lorenz and Cysewski, 2000) | Mixture of isomers, not approved for human consumption (Li et al., 2011) |
|                   | Overexpress idi and dxs and balance expression of crtE, crtB, crt, crtY, and crtZ from Pantoea ananatis and crtV148 (NpF4798) from Nostoc punctiforme, which were inserted into the chromosome | 1.4 mg/g dww (20-fold) (Lemuth et al., 2011)                                                            | E. coli |                                                                  |                                                          |
| Levopimaradiene   | Combinatorially mutate the GGPPS–LPS pathway            | 700 mg/l (2,600-fold) (Leonard et al., 2010)                                                              | E. coli | Young Ginkgo biloba trees 1–7 mg/g dry weight (Matsuda and Schepmann, 2008) | <3% Overall yield (Matsuda and Schepmann, 2008)           |
| Lycopene²         | Express Erwinia carotenoid biosynthesis gene cluster and idi from Haematococcus pluvialis         | 1.03 mg/g dww (4.5-fold) (Kajiwara et al., 1997)                                                         | E. coli | Tomatoes 0.15–0.25 mg/g (Rath, 2009)                               | 0.13 mg/g and 70% trans configurations (Olempska-Beer, 2006) |
|                   | Redesign the global regulatory system, the Ntr regulon | 160 mg/l (from 0 mg/l) (Farmer and Liao, 2000)                                                           | E. coli | 94–96% trans configurations (Olempska-Beer, 2006)                  |                                                          |
|                   | Overexpress the catalytic domain of HMG and disrupt ERG9 | 7.8 mg/g dww (7-fold) (Shimada et al., 1998)                                                             | C. utilis |                                                                  |                                                          |

(Continued)
| Isoprenoid | Approach<sup>1</sup> | Microbial production (fold improvement) | Microbe | Natural source and extraction | Chemical synthesis |
|-----------|---------------------|---------------------------------------|---------|-----------------------------|-------------------|
|            |                     | 12.32 mg/g dcw (4-fold) | *E. coli* |                             |                   |
| Overexpress genes identified by the FSEOF strategy combined with gene knockouts | (Choi et al., 2010) |
| Overexpress and knockout genes selected from a metabolic landscape | 16 mg/g dcw (4-fold) | *E. coli* |                             |                   |
| Use “global transcription machinery engineering” to improve phenotypes | 7.7 mg/g (1.8-fold) | *E. coli* |                             |                   |
| Optimize DXP pathway with “multiplex automated genome engineering” | 9 mg/g dcw (5-fold) | *E. coli* |                             |                   |
| Miltiradiene | Fuse SmCPS and SmKSL as well as BTS1 and ERG20 | 365 mg/l (340-fold) | *S. cerevisiae* | *Salvia miltiorrhiza* | 4 mg/ml of the precursor salvianolic acid B | (Gu et al., 2008) |
| Patchoulol | Replace the native ERG9 promoter with the methionine repressible MET3 promoter | 16.9 mg/l (1.5-fold) | *S. cerevisiae* | *Pogostemon cablin* | 6% Overall yield of the precursor norpatchoulenol | (Kolek et al., 2009) |
|           | Fuse the native farnesyl diphosphate synthase and the heterologous patchoulol synthase and repress ERG9 | 40.9 mg/l (2-fold) | *S. cerevisiae* |                             |                   |
| Taxadiene | Express genes for GGPPS, taxadiene synthase, three cytochrome P450 hydroxylases, and three acyl/aryl CoA dependent transferases and build a five step taxoid pathway | 1 mg/l (100-fold) | *S. cerevisiae* | *Taxus brevifolia* | 18–20% Overall yield | (Mendoza et al., 2012) |
| Express genes for geranylglycerol diphosphate synthase from *Sulfolobus acidocaldarius* and a codon-optimized taxadiene synthase from *Taxus chinensis* | 8.7 mg/l (40-fold) | *S. cerevisiae* |                             |                   |
| Vary small pathway modules simultaneously to determine the optimally balanced complete pathway (“multivariate modular pathway engineering”) | 1 g/l (15,000-fold) | *E. coli* |                             |                   |
| Zeaxanthin<sup>2</sup> | Overexpress different combinations of *idi* from *Xanthophyllomyces dendrorhous*, *dvr* from *Sulfolobus acidocaldarius*, and native *dks* | 1.6 mg/g dcw (3.5-fold) | *E. coli* | *Tagetes erecta’s red flowers 23% dry weight* | 12% Overall yield of racemic mix | (Khachik and Chang, 2009) |
| Use the “ordered gene assembly in Bacillus subtilis (OGAB) method” to determine optimal gene order | 820 µg/g dcw (4.4-fold) | *E. coli* |                             |                   |

<sup>1</sup>Continued

<sup>2</sup>Continued
are currently manufactured or will be manufactured in the near future.

**ISOPRENOID PATHWAY**

Although isoprenoids include a wide range of compounds, they are synthesized through a common metabolic pathway. The isoprenoid pathway (Figure 1) begins with the conversion of acetyl-CoA to isopentenyl diphosphate (IPP). IPP is then isomerized to dimethylallyl diphosphate (DMAPP), which forms geranyl diphosphate (GGPP). At this point different cursor compounds IPP and DMAPP, the mevalonate pathway, and the methylerythritol phosphate (MEP) pathway. Thus, researchers are currently considered as an important step in the production of isoprenoids.

**CAROTENOIDS**

Carotenoids are among the first natural products whose titers were improved through synthetic biology tools. Early work on the microbial production focused on increasing the supply of intermediates in the first steps of the isoprenoid pathway. In 1997, the production of carotenoids in E. coli was improved by a factor of 2.7, for a total of 1.3 mg/dry cell weight (dcw), by introducing heterologous genes for IPP isomerase (Kajiwara et al., 1997). Albrecht et al. (1999) increased the nutrients β-carotene and zeaxanthin 3.5-fold, to reach 1.5 and 1.6 mg/dcw respectively, by overexpressing control elements (RBS sequestering sequences, mRNA secondary structures, and RNase cleavage sites) were screened to select the E. coli strain that produced sevenfold more mevalonate (Pilger et al., 2006). Shiba et al. amplified the precursor flux to the mevalonate pathway in S. cerevisiae by overexpressing acetaldehyde dehydrogenase and incorporating Salmonella enterica’s acetyl-CoA synthetase. This kept more carbon flow in the cytosol, as opposed to the mitochondria, resulting in more mevalonate (Shiba et al., 2007). To increase lycopene production by boosting the precursor supply, a synthetic mevalonate pathway was assembled in E. coli, which included yeast mevalonate kinase (yMVK), human 5-phosphomevalonate kinase (hPMK), yeast 5-diphosphomevalonate decarboxylase (yPMD), and E. coli IPP/DMAPP isomerase (Rodriguez-Villalon et al., 2008). Duerber et al. (2009) created synthetic protein scaffolds to co-localize mevalonate pathway enzymes, leading to a 77-fold improvement in product titers. This approach demonstrated that high production of mevalonate can be achieved with low enzyme expression and reduced metabolic burden.

**Table 1 | Continued**

| Isoprenoid        | Approach                          | Microbial production (fold improvement) | Microbe     | Natural source and extraction | Chemical synthesis                  |
|-------------------|-----------------------------------|-----------------------------------------|-------------|------------------------------|--------------------------------------|
| α-Santalene       | Replace the native ERG9 promoter with the glucose-responsive HXT7 promoter, delete the genes for lipid phosphate phosphatase and pyrophosphate phosphatase, and overexpress a truncated 3-hydroxyl-3-methyl-glutaryl-CoA reductase | 0.21 mg/g dcw (3.4-fold) (Scalinati et al., 2012) | S. cerevisiae | Santalum album 1–2% by weight of oil (Jones et al., 2011) | 8% Overall yield (Bastiaansen et al., 1996) |
| β-Carotene        | Overexpress different combinations of idi from Xanthophyllomyces dendrorhous, dxx from Sulfolobus acidocaldarius, and native dxs | 1.5 mg/g dcw (3.5-fold) (Albrecht et al., 1999) | E. coli | Mostly Dunaliella salina 300 mg/m²/day (Hosseini Tafreshi and Shariati, 2009) | 85% Yield using triphenyl-phosphine oxide, which is harmful to aquatic organisms (USDA, 2011) |
|                   | Replace the native promoters for the chromosomal genes dxs, ispDispF, idi, and ispB with strong T5 bacteriophage promoters | 6 mg/g dcw (24.5-fold) Yuan et al., 2006 | E. coli |                             |                                      |
different combinations of the genes for IPP isomerase from *Xanthophyllomyces dendrorhous*, GGPP synthase from *Sulfolobus acidocaldarius*, and native DXP synthase. More than a 50-fold improvement was made in the production of astaxanthin, used to treat several degenerative nerve diseases, by boosting IPP and GGPP formation as well as expressing the gene cluster *crtBIYZW* from *Agrobacterium aurantiacum* in *E. coli* for a total of 1.4 mg/g dcw (Wang et al., 1999). However, unhindered metabolite production can lead to metabolic imbalance. Farmer and Liao (2000) redesigned a global regulatory system in *E. coli* to allow lycopene production only in the presence of sufficient glucose, as indicated by acetyl phosphate availability. This control loop decreased the metabolic imbalance, thus increasing the final yield of the nutritional supplement. Shimada et al. (1998) also improved lycopene production.
production by focusing on the later steps of the isoprenoid pathway. In *Candida utilis* that expressed exogenous *crtE*, *crtB*, and *crtI*, the gene *ERG9*, which diverts FPP to the ergosterol pathway, was disrupted and the catalytic domain of HMG was overexpressed, resulting in 7.8 mg lycopene/g dcw. Novel carotenoids were created in *E. coli* through the expression of mutagenic libraries of phytoene desaturase and lycopene cyclase, enzymes that regulate branchpoints in the later stages of carotenoid biosynthesis. A wide variety of metabolites, including 3,4,5′,4′-tetrahydrolycopene, a fully conjugated carotenoid, and torulene, a new cyclic carotenoid, were observed (Schmidt-Dannert et al., 2000).

More recently, powerful new techniques have been employed to further improve carotenoid production. Jin and Stephanopoulos (2007) constructed a lycopene production metabolic landscape using *E. coli* strains that incorporated different combinations of overexpression and knockout targets. From this landscape, the best combination of genes increased lycopene production to 16 mg/g dcw. β-carotene production reached 6 mg/g dcw by replacing the native *E. coli* promoters for the chromosomal genes ddx, ispDispF, idh, and ispB with strong T5 bacteriophage promoters. Modifying chromosomal genes, instead of introducing high-copy vectors to overexpress the target genes, decreased the metabolic burden (Yuan et al., 2006).

Lemuth et al. also used similar techniques by balancing expression of *crtE*, *crtB*, *crtI*, *crtY*, and *crtZ* from *Pantoea ananatis* and *crtW*148 (NpF4798) from *Nostoc punctiforme*, which were inserted into the chromosome of *E. coli*. This plasmid-free strain created astaxanthin as its only carotenoid at 1.4 mg/g dcw (Lemuth et al., 2011). Using the "ordered gene assembly in *Bacillus subtilis* (OGAB) method" to put together multiple genes in a single step, Nishizaki et al. (2007) determined the optimum gene order which subsequently produced 820 μg g zeaxanthin/g dcw. The "flux scanning based on enforced objective flux" (FSEOF) strategy identified targets for gene amplification that were not intuitive. When combined with gene knockouts, 12.32 mg lycopene/g dcw was achieved (Choi et al., 2010). Alper and Stephanopoulos (2007) randomly mutated the *E. coli* sigma factor σ^32^ to look for desired complex phenotypes. This "global transcription machinery engineering" (gTME) improved lycopene production. "Multixplex automated genome engineering" (MAGE) was proposed by Wang et al. They modified 24 genetic components at once from a degenerate pool of synthetic DNA, achieving a fivefold increase in lycopene production in just 3 days (Wang et al., 2009).

**ARTEMISININ**

The microbial production of the potent anti-malaria drug artemisinin has utilized a number of advances in the synthetic biology field. Balancing metabolic flux with the codon-optimized amorphadiene synthase gene improved the titer of amorphadiene, an artemisinin precursor, beyond what had been accomplished by increasing IPP precursor supply (Martin et al., 2003). Ro et al. (2006) redesigned the mevalonate pathway in *S. cerevisiae* to increase production of FPP and introduced *Artemisia annua*’s amorphadiene synthase and cyclochrome P450 for the final oxidation steps. The modifications resulted in 100 mg/l of artemisinic acid (Ro et al., 2006). Anthony et al. (2009) achieved the amorphadiene titer of 293 mg/l by identifying the limiting reaction enzymes and balancing gene expression through plasmid copy number and promoter strength. Building upon all of the previous works in the Keasling lab, production of >40 g/l amorphadiene was achieved by overexpressing every enzyme in the mevalonate pathway and modifying fermentation conditions. Subsequently, the amorphadiene was chemically converted to dihydroartemisinic acid, the precursor of the antimalarial agent artemisinin (Westfall et al., 2012).

A. annua’s amorphadiene synthase, codon-optimized and placed under the control of the *psf* promoter, and the native FPP synthase were expressed in a genome-minimized strain of *Streptomyces avermitilis*. This approach led to heterologous biosynthesis of 30 mg/l of amorphadiene while not producing any of the major endogenous secondary metabolites (Komatsu et al., 2010). Fari et al. (2011) co-localized heterologous FDP synthase and amorphadiene synthase to the mitochondria to improve the amorphadiene titer by 20-fold, for a total of 20 mg/l.

**DITERPENES AND OTHER SESQUITERPENES**

Biosynthetic pathways for various diterpenes and sesquiterpenes have also been engineered for improved production through synthetic biology. To maximize production of several sesquiterpenes, Asadollahi et al. replaced the native *ERG9* promoter, which is responsible for diverting the terpenoid precursor FPP to a competing pathway, with the methionine repressible MET3 promoter. After optimizing methionine levels, 16.9 mg/l of patchoulol, the starting compound in the chemical synthesis of the chemotherapeutic drug paclitaxel (Taxol), was achieved (Asadollahi et al., 2008). Scalcinati et al. chose to control *ERG9* expression by coupling it with the glucose-responsive *HXT1* promoter. In addition to using this promoter, the genes encoding lipid phosphate phosphatase and pyrophosphate phosphatase were deleted, and a truncated 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) was overexpressed to produce ω-santalene, a skin cancer chemopreventive, at 0.21 mg/g dcw (Scalcinati et al., 2012). The native FPP synthase and the heterologous patchoulol synthase were fused to reduce metabolic diffusion distance between enzymes, increasing patchoulol production twofold, to a total of 40.9 mg/l, in *S. cerevisiae* (Albertsen et al., 2011). Miltiradiene, related to the Chinese medicinal herb *Salvia miltiorrhiza*, was produced up to 365 mg/l in a 151 bioreactor, by fusing labdadienyl/copalyl diphosphate synthase (SmCPS) and kaurene synthase-like (SmKSL) as well as GGPP synthase (BTS1) and FPP synthase (ERG20) in *S. cerevisiae* (Zhou et al., 2012). The capacity of downstream pathways can also limit titters. The geranylgeranyl diphosphate synthase – levopimaradiene synthase (GGPPs – LPS) pathway was combinatorially mutated to accommodate the engineered upsurge in precursors. This approach led to a 2,600-fold increase, for a total of 700 mg/l, of the diterpene levopimaradiene, used to produce the ancient medicinal ginkgolides (Leonard et al., 2010).

**PACLITAXEL**

Application of synthetic biology tools to microbial production of the cancer chemotherapy drug paclitaxel will decrease its cost and increase its availability. Paclitaxel, known as Taxol, is a potent chemotherapy drug, which is very difficult to chemically synthesize (Chandran et al., 2011) and is extracted at very low efficiency from the bark of the rare Pacific yew (Aijikumar et al., 2008). Dejong et al. (2006) were the first to express genes for a portion of the Taxol pathway in *S. cerevisiae*, but production levels of the
Taxol intermediate, taxadiene, were low. Several changes to taxadiene synthesis in yeast were introduced, including an alternate geranylgeranyl diphosphate synthase from *S. acidocaldarius* and a codon-optimized taxadiene synthase from *Taxus chinensis*, ultimately resulting in a 40-fold titer increase to 8.7 mg/l (Engels et al., 2008). Using *E. coli* as a host, Ajikumar et al. (2010) divided the metabolic pathway into smaller modules and varied the expression levels simultaneously to determine the optimally balanced pathway without requiring high throughput screening. This “multivariate modular pathway engineering” resulted in the taxadiene titer of 1 g/l. Although challenges remain for the biosynthesis of Taxol and other compounds, the range of advancements in isoprenoid production by microbial biosynthesis shows promise for increasing their availability at reduced cost.

**CONCLUSION**

The past decade has witnessed the potential of synthetic biology to make the microbial isoprenoid production become industrially relevant. However, further improvements in yield and expansion to new medically important compounds can be attained through the development of additional tools. An incomplete understanding of the complexity of biosynthetic pathways limits the ability to fully forward engineer microbial production (Nielsen and Keasling, 2011; Stephanopoulos, 2012). Continued innovations in systems biology to elucidate the complex regulatory and metabolic networks will advance the predictive potential of mathematical models, and therefore the ability to generate optimized microbial cell factories (Jarboe et al., 2010; Nielsen and Keasling, 2011; Keasling, 2012). Genome mining, scanning genome sequences for natural functions, will accelerate the rate of new compound discoveries. Improved enzyme engineering will also support the *de novo* design of biosynthetic pathways (Ajikumar et al., 2008; Jarboe et al., 2010). Moreover, biological devices built from well-characterized and standardized genetic parts can be used to control metabolic pathways. Incorporation of these strategies would lead to engineered microbes for industrial-scale production of medically important compounds.

**REFERENCES**

Ajikumar, P. K., Tyo, K., Carlsen, S., Mucha, O., Phon, T. H., and Stephanopoulos, G. (2008). Terpenoid opportunities for biosynthesis of natural product drugs using engineered microorganisms. *Mol. Pharm.* 5, 167–190.

Ajikumar, P. K., Xiao, W. H., Tyo, K. E., Wang, Y., Simeon, F., Leonard, E., et al. (2010). Isoprenoid pathway optimization for taxol precursor overproduction in *Escherichia coli*. Science 330, 70–74.

Albertsen, L., Chen, Y., Bach, L. S., Rattliff, S., Maury, J., Brix, S., et al. (2011). Diversion of flux towards sesquiterpene production in *Saccharomyces cerevisiae* by fusion of host and heterologous enzymes. *Appl. Environ. Microbiol.* 77, 1033–1040.

Albrecht, M., Misawa, N., and Sandmann, G. (1999). Metabolic engineering of the terpenoid biosynthetic pathway of *Escherichia coli* for production of the carotenoids β-carotene and zeaxanthin. *Biotechnol. Lett.* 21, 791–795.

Alper, H., and Stephanopoulos, G. (2007). Global transcription machinery engineering: a new approach for improving cellular phenotype. *Metab. Eng.* 9, 258–267.

Anthony, J. R., Anthony, L. C., Nowrouzi, E., Kwon, G., Newman, J. D., and Keasling, J. D. (2009). Optimization of the mevalonate-based isoprenoid biosynthetic pathway in *Escherichia coli* for production of the anti-malarial drug precursor amorpha-4,11-diene. *Metab. Eng.* 11, 13–19.

Asadollahi, M. A., Maury, J., Moller, K., Nielsen, K. F., Schalk, M., Clark, A., et al. (2008). Production of plant sesquiterpenes in *Saccharomyces cerevisiae*: effect of ERG9 repression on sesquiterpene biosynthesis. *Biotechnol. Bioeng.* 99, 666–677.

Bastiaansen, P. F. M. F., Wijnberg, J. B. P. A., and De Groot, A. (1996). A new enantiopspecific synthesis of a-santalanes via homofragmentation of 1,4-diole monosulfonate esters. *J. Org. Chem.* 61, 4955–4958.

Chandran, S. S., Kealey, J. T., and Reeves, G. D. (2011). Microbial production of isoprenoids. *Process Biochem.* 46, 1703–1710.

Chang, M. C., and Keasling, J. D. (2006). Production of isoprenoid pharmaceuticals by engineered microbes. *Nat. Chem. Biol.* 2, 674–681.

Chenler, J. A., Yan, Y., and Korfas, M. A. (2006). Biosynthesis of isoprenoids, polysaturated fatty acids and flavonoids in *Saccharomyces cerevisiae*. *Microb. Cell Fact.* 5, 20.

Choi, H. S., Lee, S. Y., Kim, T. Y., and Woo, H. M. (2010). In silico identification of gene amplification targets for improvement of lycopene production. *Appl. Environ. Microbiol.* 76, 3097–3105.

Das, A., Yoon, S. H., Lee, S. H., Kim, J. Y., Oh, D. K., and Kim, S. W. (2007). An update on microbial carotenoid production: application of recent metabolic engineering tools. *Appl. Microbiol. Biotechnol.* 77, 505–512.

Dejong, J. M., Liu, Y., Bollon, A. P., Long, R. M., Jennewein, S., Williams, D., et al. (2006). Genetic engineering of taxol biosynthetic genes in *Saccharomyces cerevisiae*. *Biotechnol. Bioeng.* 93, 212–224.

Du, J., Shao, Z., and Zhao, H. (2011). Engineering microbial factories for synthesis of value-added products. *J. Ind. Microbiol. Biotechnol.* 38, 873–890.

Duebert, J. E., Wu, G. C., Malmirchegini, G. R., Moon, T. S., Petzold, C. J., Ullal, A. V., et al. (2009). Synthetic protein scaffolds provide modular control over metabolic flux. *Nat. Biotechnol.* 27, 753–759.

Engels, B., Dähm, F., and Jennewein, G. (2008). Metabolic engineering of taxadiene biosynthesis in yeast as a first step towards taxol (paclitaxel) production. *Metab. Eng.* 10, 201–206.

Farhi, M., Marzheva, E., Masi, T., Marcox, E., Fyal, Y., Ovadis, M., et al. (2011). Harnessing yeast subcellular compartments for the production of plant terpenoids. *Metab. Eng.* 13, 474–481.

Farmer, W. R., and Liao, J. C. (2000). Improving lycopene production in *Escherichia coli* by engineering metabolic control. *Nat. Biotechnol.* 18, 533–537.

Gu, M., Su, Z. G., and Janson, J. C. (2008). One-step purification of 3,4-dihydroxymphenylacetic acid, salvianolic acid B, and protocatechuic acid from *Salvia miltiorrhiza* Bunge by isocratic stepwise hydrogen bond adsorption chromatography on cross-linked 12% agarose. *J. Chromatogr. Sci.* 46, 165–168.

Hezari, M., Ghasalberti, E. L., et al. (2011). *Sandralwood fragrance biosynthesis involves sesquiterpene synthases of both the terpene synthase (TPS-a and TPS-b) subfamilies, including santalene synthases*. *J. Biol. Chem.* 286, 17445–17454.

Kajiwara, S., Fraser, P. D., Kondo, K., and Masuda, S. (2011). Genome mining, scanning genome sequences for natural functions, will accelerate the rate of new compound discoveries. Improved enzyme engineering will also support the *de novo* design of biosynthetic pathways (Ajikumar et al., 2008; Jarboe et al., 2010). Moreover, biological devices built from well-characterized and standardized genetic parts can be used to control metabolic pathways. Incorporation of these strategies would lead to engineered microbes for industrial-scale production of medically important compounds.
Isoprenoid production and synthetic biology

Keasling, J. D. (2012). Synthetic biology and the development of tools for metabolic engineering. Metab. Eng. 14, 189–195.

Khachik, E., and Chang, A. N. (2009). Total synthesis of (3R,3′R,6′R)-lutein and its stereoisomers. J. Org. Chem. 74, 3875–3885.

Klein-Marcuschamer, D., Ajikumar, P. K., and Stephanopoulos, G. (2007). Engineering microbial cell factories for biosynthesis of isoprenoid molecules: beyond lycopene. Trends Biotechnol. 25, 417–424.

Kolek, T., Seipenster, A., and Swidz, A. (2009). The microbiological hydorxylation of patchoul in Abdisia coerulea and Macor hilaclis. Biocatal. Biotransformation 27, 102–106.

Komatsu, M., Uchiyama, T., Omura, S., Cane, D. E., and Ikeda, H. (2010). Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism. Proc. Natl. Acad. Sci. U.S.A. 107, 2646–2651.

Lemuth, K., Steuer, K., and Albermann, C. (2011). Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin. Microb. Cell Fact. 10, 29.

Leonard, E., Ajikumar, P. K., Thayer, K., Xiao, W. H., Mo, J. D., Tidor, B., et al. (2010). Combining metabolic and protein engineering of a terpenoid biosynthetic pathway for overproduction and selectivity control. Proc. Natl. Acad. Sci. U.S.A. 107, 13654–13659.

Li, J., Zhu, D., Niu, J., Shen, S., and Wang, G. (2011). An economic assessment of astaxanthin production by large scale cultivation of Haemato coccus pluvialis. Biotechnol. Adv. 29, 568–574.

Li, X. B., Wang, W., Zhou, G. J., Li, Y., Xie, X. M., and Zhou, T. S. (2012). Production of salvianolic acid B in roots of Salvia miltior rhiza (Danshen) during the post-harvest drying process. Molecules 17, 2388–2407.

Liu, C., Zhao, Y., and Wang, Y. (2006). Artesiminin: current state and perspectives for biotechnological production of an antimalarial drug. Appl. Microbiol. Biotechnol. 72, 11–20.

Lorenz, R. T., and Cysewski, G. R. (2006). Chemical potential for Haemato coccus microalgae as a natural source of astaxanthin. Trends Biotechnol. 18, 160–167.

Martin, V. I., Pitera, D. J., Withers, S. T., Newman, J. D., and Keasling, J. D. (2003). Engineering a mevalonate pathway in Esherichia coli for production of terpenoids. Nat. Biotechnol. 21, 796–802.

Matsuda, S. P. T., and Scheffmann, H. G. (2008). Ginkgo biloba leuopmara diene synthase. United States Patent Application 11/166,996 [accessed May 20, 2008].

Maury, J., Asadollahi, M. A., Moller, K., Schalk, M., Clark, A., Formenti, L. R., et al. (2008). Reconstruction of a bacterial isoprenoid biosynthetic pathway in Saccharomyces cerevisiae. FEBS Lett. 582, 4032–4038.

Mendoza, A., Ishihara, Y., and Baran, P. S. (2012). Scalable enantioselective total synthesis of taxanes. Nat. Chem. 4, 21–25.

Misawa, N. (2011). Pathway engineering for functional isoprenoids. Curr. Opin. Biotechnol. 22, 627–633.

Misawa, N., and Shimada, H. (1997). Metabolic engineering for the production of carotenoids in non-carotenogenic bacteria and yeasts. J. Biotechnol. 59, 169–181.

Nakagawa, A., Minami, H., Kim, J. S., Koyanagi, T., Katayama, T., Sato, F., et al. (2011). A bacterial platform for fermentative production of plant alkaloids. Nat. Comm. 2, 126.

Nielsen, J., and Keasling, J. D. (2011). Synergies between synthetic biology and metabolic engineering. Nat. Biotechnol. 29, 695–695.

Nishizaki, T., Tsuge, K., Itaya, M., Nishizawa, Y., Maury, J., Schalk, M., et al. (2012). Engineering of the pyruvate dehydroge nase bypass in Saccharomyces cerevisiae for high-level production of isoprenoids. Metab. Eng. 9, 160–168.

Shiba, Y., Paradise, E. M., Kirby, J., Ro, D. K., and Keasling, J. D. (2007). Engineering of the pyruvate dehydrogenase bypass in Saccharomyces cerevisiae to enhance carotenoid production. Curr. Opin. Biotechnol. 18, 750–753.

Sladky, J., and Stephanopoulos, G. (2012). Synthetic biology and metabolic engineering. ACS Synth. Biol. 1, 514–525.

Tang, W. L., and Zhao, H. (2009). Increased carotenoid production by the food yeast Candida utilis through metabolic engineering of the isoprenoid pathway. Appl. Environ. Microbiol. 64, 2676–2680.

Stanikovski, I. (2004). Zeaxanthin. Geneva: 63rd Joint FAO/WHO Expert Committee on Food Additives, I–7.

Stephanopoulos, G. (2012). Synthetic biology and metabolic engineering. ACS Synth. Biol. 1, 514–525.

Tang, W. L., and Zhao, H. (2009). Industrial biotechnology: tools and applications. Biotechnol. J. 4, 1725–1739.

USDIA. (2011). B-Carotene Handling and Processing. Washington: Techni cal Services Branch for the USDA National Organic Program, I–20.

Walter, M. H., and Strack, D. (2011). Carotenoids and their cleavage products: biosynthesis and functions. Nat. Prod. Rep. 28, 663–692.

Wang, C. W., Oh, M. K., and Liao, J. C. (1999). Engineered isoprenoid pathway enhances astaxanthin production in Esherichia coli. Biotechnol. Bioeng. 62, 235–241.

Wang, H. H., Isaacs, F. J., Carr, P. A., Westfall, P. J., Pitera, D. J., Lenihan, J. R., Eng, D., Woolard, F. X., Regentin, R., et al. (2012). Production of amorphadiene in yeast, and its conversion to dihydroar temisinic acid, precursor to the antimalarial agent artemisinin. Proc. Natl. Acad. Sci. U.S.A. 109, E111–E118.

Winter, J. M., and Tang, Y. (2012). Synthetic biological approaches to natural product biosynthesis. Curr. Opin. Biotechnol. 23, 736–743.

Withers, S. T., and Keasling, J. D. (2007). Biosynthesis and engineering of isoprenoid small molecules. Appl. Microbiol. Biotechnol. 73, 980–990.

Wu, J., Du, G., Zhou, J., and Chen, J. (2013). Metabolic engineering of Escherichia coli for (2S)-pinocembrin production from glucose by a modular metabolic strategy. Metab. Eng. 16, 48–55.

Yuan, L. Z., Rouviere, P. E., Larossa, R. A., and Suh, W. (2006). Chromosomal promoter replacement of the isoprenoid pathway for enhancing carotenoid production in E. coli. Metab. Eng. 8, 79–85.

Zhou, Y. J., Gao, W., Bong, Q., Jin, G., Chu, H., Liu, W., et al. (2012). Modular pathway engineering of diterpenoid syntheses and the mevalonic acid pathway for miltiradiene production. J. Am. Chem. Soc. 134, 3234–3241.

Zhu, C., and Cook, S. P. (2012). A concise synthesis of (+)-ar teminisin. J. Am. Chem. Soc. 134, 15377–15379.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 January 2013; accepted: 14 March 2013; published online: 04 April 2013.

Citation: Immethun CM, Hoynes-O’Connor AG, Balassy A and Moon TS (2013) Microbial production of isoprenoids enabled by synthetic biology. Front. Microbiol. 4:75. doi: 10.3389/fmicb.2013.00075

This article was submitted to Frontiers in Microbiology, Ecotoxicology and Bioremediation, a specialty of Frontiers in Microbiology. Copyright © 2013 Immethun, Hoynes-O’Connor, Balassy and Moon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.